Minor RAS
MINOR
the mean baseline of USS before treatment of 18 patients with minor RAS was 28.8 ± 4.4, and this was reduced by almost 30% after 3 months treatment to 20.2 ± 8.9 (p < 0.001). The improvement in the USS continued incrementally during the study period. At the end of the study, the mean USS had improved by more than 50% when compared with the baseline (p < 0.001) (Table 